Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Bio Green Med Solution's Debt-to-EBITDA or its related term are showing as below:
BGMS's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.14 * Ranked among companies with meaningful Debt-to-EBITDA only.
Bio Green Med Solution (NAS:BGMS) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Bio Green Med Solution Debt-to-EBITDA Related Terms
Bio Green Med Solution Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Bio Green Med Solution's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BGMS vs SILO, ALZN, ENVB: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Bio Green Med Solution's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio Green Med Solution Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio Green Med Solution's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bio Green Med Solution's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Bio Green Med Solution (BGMS) has a Debt-to-EBITDA of 0.00 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bio Green Med Solution. According to the industry distribution chart, Bio Green Med Solution ranks #999999 out of 291 companies in the Biotechnology industry.
Is Bio Green Med Solution's Debt-to-EBITDA too high?
Bio Green Med Solution's current Debt-to-EBITDA is 0.00. Based on the distribution chart, Bio Green Med Solution ranks #999999 out of 291 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Bio Green Med Solution has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bio Green Med Solution's Debt-to-EBITDA compare to SILO and ALZN?
According to the Biotechnology industry distribution chart, Bio Green Med Solution ranks #999999 out of 291 companies for Debt-to-EBITDA. This places Bio Green Med Solution in the lower half of its industry. The industry median Debt-to-EBITDA is 1.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bio Green Med Solution. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio Green Med Solution's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Green Med Solution stock overvalued right now?
Based on GuruFocus' analysis, Bio Green Med Solution (BGMS) is currently considered Possible Value Trap. The stock's GF Value™ is $2.56, compared to a current price of $0.92 — trading 63.9% below its estimated fair value. The current Debt-to-EBITDA is 0.00. Bio Green Med Solution's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Bio Green Med Solution (BGMS), the current Debt-to-EBITDA is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio Green Med Solution (BGMS) Overvalued in 2026?
Based on GuruFocus' analysis, Bio Green Med Solution stock appears to be undervalued.
The current stock price of $0.92 is trading 63.9% below its estimated GF Value™ of $2.56.
GuruFocus considers Bio Green Med Solution to be Possible Value Trap.
Key valuation signals for BGMS:
Debt-to-EBITDA: 0.00
GF Value™: $2.56 vs. price of $0.92 (63.9% below fair value)
No single metric tells the full story. See the BGMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio Green Med Solution Inc is engaged in the supply and trading of protective and fire safety equipment. The company distributes products such as fire extinguishers, foam systems, fire-resistant doors, personal protective equipment, and safety apparel. It also provides fire safety systems, including sprinkler systems, fire alarm systems, valves, and CO2 systems. The company operates across commercial, industrial, healthcare, and residential sectors, with a focus on distribution and compliance with applicable safety standards.
45GF Score
Get the complete analysis for BGMS
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGMS has been successfully added to your 
